Industry
Bedrocan to manufacture cannabis products in Denmark
The new facility will ‘improve security of supply’ and meet demand from patients across Europe.
The Dutch producer of medicinal cannabis is to open a new facility in Denmark in order to meet demand from patients across Europe.
Bedrocan, the sole producer of medicinal cannabis in the Netherlands since 2003, has announced it will establish a new facility to manufacture its products in Denmark.
The company says its new GMP-approved facility, located in Køge near Copenhagen, will allow it to expand production capacity to meet the growing international demand for its products.
Bedrocan’s products are used by patients on prescription and as pharmaceutical raw materials and active pharmaceutical ingredients by researchers and pharmaceutical companies in multiple countries around the world.
It currently operates two indoor production facilities, a plant research and development facility, and a laboratory in the Netherlands. However, under the current legal framework in Bedrocan’s products are only available via the Dutch Office of Medicinal Cannabis (OMC), which is part of the Ministry of Health.
With its Danish site, Bedrocan expects to significantly improve the availability of its products to patients globally, with the freedom to conduct business directly with other commercial entities.
The new facility is expected to be operational by the end of 2023, with around 40 staff on board.
It will begin with the production of known Bedrocan varieties, including Bedrocan and Bediol oil, plus a new high-CBD variety, with products initially intended to supply the European market.
Bedrocan CEO Jaap Erkelens.
Bedrocan CEO Jaap Erkelens, said the move would benefit patients as access to its products would be less dependent on ‘political agreements’.
“At Bedrocan, the patient comes first,” said Mr Erkelens in a statement to Cannabis Health.
“The expansion to Denmark will allow us to serve them even better in the future. The availability of Bedrocan products in Europe will soon be less dependent on political agreements between countries. This improves the security of supply, which is good for all patients.”
Last year UK firm Target Healthcare secured a Home Office license to produce Bedrocan oils for patients in the UK.
-
Industry6 months agoFirst UK-grown cannabis medicine expected by end of 2023
-
News6 months agoUK government accepts ACMD recommendations for CBD products
-
News5 months agoEurope’s first legal cannabis dispensaries to open under sixth Swiss pilot
-
News6 months agoUK government to permit electronic prescribing of cannabis medicines
-
Science4 months agoMedical cannabis doesn’t impair cognitive function – study
-
Industry5 months agoFirst Jersey-grown medicinal cannabis product to hit UK market
-
News5 months agoFive years of medical cannabis, five NHS prescriptions – how did we get here?
-
Patients6 months ago“They just didn’t care” – cannabis patient arrested on driving lesson speaks out
